Daily Stock Analysis, EVOK, Evoke Pharma Inc, priceseries

Evoke Pharma Inc. Daily Stock Analysis
Stock Information
Open
1.12
Close
1.23
High
1.23
Low
1.11
Previous Close
1.09
Daily Price Gain
0.14
YTD High
3.26
YTD High Date
Feb 20, 2019
YTD Low
0.50
YTD Low Date
Jun 26, 2019
YTD Price Change
-1.32
YTD Gain
-51.76%
52 Week High
3.40
52 Week High Date
Sep 18, 2018
52 Week Low
0.50
52 Week Low Date
Jun 26, 2019
52 Week Price Change
-1.42
52 Week Gain
-53.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
2.07
Jan 11. 2017
2.44
6 Trading Days
17.71%
Link
LONG
Sep 1. 2017
2.60
Sep 26. 2017
3.19
16 Trading Days
22.52%
Link
LONG
Apr 11. 2018
2.20
Apr 23. 2018
2.35
8 Trading Days
6.91%
Link
LONG
May 4. 2018
2.51
May 25. 2018
2.90
15 Trading Days
15.58%
Link
LONG
Aug 28. 2018
2.60
Sep 19. 2018
3.20
15 Trading Days
23.03%
Link
LONG
Dec 28. 2018
2.30
Jan 16. 2019
2.52
12 Trading Days
9.78%
Link
Company Information
Stock Symbol
EVOK
Exchange
NasdaqCM
Company URL
http://www.evokepharma.com
Company Phone
858-345-1494
CEO
David A. Gonyer
Headquarters
California
Business Address
420 STEVENS AVENUE, SUITE 370, SOLANA BEACH, CA 92075
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001403708
About

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops EVK-001 for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn and David A. Gonyer on January 29, 2007 and is headquartered in Solana Beach, CA.

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company develops EVK-001, a metoclopramide nasal spray, which is in Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Evoke Pharma, Inc. was founded in 2007 and is headquartered in Solana Beach, California.